Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for HIV-associated Inflammation and Cognitive Dysfunction
NCT03384784Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Oct 2017
- Primary completion
- May 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galantamine in HIV-associated neurocognitive disorder (HAND), sponsored by University of Pennsylvania. Primary endpoint: Change in Cognition at Week 28. Started Oct 2017; status: completed.
02
Drugs
galantamine
03
Conditions
HIV-associated neurocognitive disorder (HAND)
Beyond the preview
Go deeper on NCT03384784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384784.